+1 for CPP
From: epp-dev-bounces@xxxxxxxxxxx [mailto:epp-dev-bounces@xxxxxxxxxxx]
On Behalf Of Johannes Dorn
Sent: Friday, September 15, 2017 9:18 AM
To: Eclipse Packaging Project <epp-dev@xxxxxxxxxxx>
Subject: Re: [epp-dev] Oxygen.1 RC4 available for testing
+1 for Java (macOS, 64 bit)
Note that I’m standing in for Andreas Sewe this time around.
Am 15. September 2017 um 14:55:47, Marvin Mueller (marvin.mueller@xxxxxxxxx) schrieb:
+1 for eclipse for Testers
regards
Marvin Mueller
BREDEX GmbH
Lindentwete 1
38100 Braunschweig
Tel.: +49 531 24330-0
Fax: +49 531 24330-99
Geschäftsführer: Andreas Vogel, Ulrich Obst, Achim Lörke
Amtsgericht Braunschweig HRB 2450
www.bredex.de
From:
epp-dev-bounces@xxxxxxxxxxx [mailto:epp-dev-bounces@xxxxxxxxxxx]
On Behalf Of Markus Knauer
Sent: Freitag, 15. September 2017 11:10
To: EPP Developer Mailing List <epp-dev@xxxxxxxxxxx>
Subject: [epp-dev] Oxygen.1 RC4 available for testing
Thanks to the availability of a machine for Mac OS signing & dmg file creation, we could re-enable building
for this platform!
As always, I'm asking for testing and +1 votes for this build.
Second, we never published the last release candidate (RC4) so far because this would mean releasing early.
But this time we had so many problems during the RC phase, and if we were able to deliver at all, it was late and most of the time incomplete (i.e. no Mac OS packages). Because of that reason I'd be interested in your opinion whether we should made these RC4
packages available on the developers build tab of the download page in order to increase the chance to find potential issues before the final release date.
What do you think?
Thanks and regards,
Markus
_______________________________________________
epp-dev mailing list
epp-dev@xxxxxxxxxxx
To change your delivery options, retrieve your password, or unsubscribe from this list, visit
https://dev.eclipse.org/mailman/listinfo/epp-dev
---------------------------------------------------------------------
This transmission (including any attachments) may contain confidential information, privileged material (including material protected by the solicitor-client or other applicable privileges), or constitute non-public information. Any use of this information by anyone other than the intended recipient is prohibited. If you have received this transmission in error, please immediately reply to the sender and delete this information from your system. Use, dissemination, distribution, or reproduction of this transmission by unintended recipients is not authorized and may be unlawful.
|
